AHSA1

Across TCGA pan-cancer cohorts, AHSA1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AHSA1 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AHSA1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AHSA1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, LUAD, and COAD are the cancer types where AHSA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.638	0.361	.014	14	view →
LUAD	OS	Tertile	All	0.641	1.000	.008	7	view →
COAD	DFS	Median	III,IV	1.000	0.897	.044	6	view →
LSCC	OS	Quartile	II,III,IV	0.927	0.615	.027	4	view →
CCRCC	OS	Median	IV	0.451	1.000	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AHSA1–PDAC (OS)

Open the PDAC breakdown →